Global Bi-Specific Antibodies Therapy Market By Clinical Trials (Preclinical, Phase I, Phase II, Phase III, Commercial); By Drug (Blinatumomab, Emicizumab, Amivantamab-vmjw, Mosunetuzumab, Others); By Route of Administration (Intravenous, Subcutaneous); By Application (Cancer, Autoimmune Diseases, Infectious Diseases, Neurologic, Cardiovascular Diseases, Others); By End-User (Hospitals, Specialty clinics, Research Institutions, Others); By Region (U.S., Canada, Mexico, Rest of North America, France, UK, Germany, Spain, Italy, Nordic Countries, Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Rest of Asia Pacific, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of MEA, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
Global bi-specific antibodies therapy market is growing at an estimated CAGR of 16.4% over the forecast period (2022 – 2030). Healthcare industry is undoubtedly one of the most valued industries today. This is truly because of medical science as it has witnessed maximum growth over the period of last few years. Courtesy of rapidly developing technology, new ways of treatments are being adopted and promoted at an extensive level. This also holds true in regards with antibodies therapies. Newly developed bi-specific antibodies therapy definitely has an edge over conventional monoclonal antibodies, as it is effectively able to bind to several targets at a single time. Owing to this, many scientists, medical experts and doctors are now extensively using bi-specific antibodies therapy to treat patients with many chronic diseases.
Bi-specific antibodies therapy is adopted on a huge level primarily because of these drugs have been successful in getting clearance in terms of several multiple clinical evaluations regarding treatment of different types of cancer which also include such tumours that might turn into malignant one.
The coronavirus pandemic which put immense strain on the healthcare sector has been a blessing in disguise for the bi-specific antibodies therapy market. Bi-specific antibodies therapy was one of the most convenient ways of treatment for those with co-morbidities as they were more likely to get infected from SARS-CoV-2 virus. This ultimately raised the demand for this therapy.
Clinical Trials Outlook
On the basis of the clinical trials, the bi-specific antibodies therapy market has been divided into preclinical, phase I, phase II, phase III and commercial. In an attempt to prove efficacy of the bi-specific antibodies therapy, many pharmaceutical companies are funding for detailed research and contributes to the growth of preclinical segment of this market. Meanwhile, the clinical phases of therapy is divided into three types, which is specifically used in the treatment of cancer.
Global Bi-Specific Antibodies Therapy Market Revenue & Forecast, (US$ Million), 2022 – 2030
Drug Outlook
The drug segment of the bi-specific antibodies therapy market has been segregated into blinatumomab, emicizumab, amivantamab-vmjw, mosunetuzumab, and others. The blinatumomab dominates in terms of market share. This is basically because it has the maximum efficacy.
Route of Administration Outlook
On the basis of route of administration, the bi-specific antibodies therapy market has been divided into intravenous and subcutaneous. Intravenous means directly through the veins, which also means more efficacy and this is exactly why this route of administration generates majority of revenue for this market.
Application Outlook
On the basis of application, the bi-specific antibodies therapy market has been segmented into cancer, autoimmune diseases, infectious diseases, neurologic diseases, cardiovascular diseases and others. The cancer segment holds upper hand over other segments in terms of market share. Lethargic lifestyle, and over consumption of carcinogenic products is causing rise in number of cancer patients. Not just radiation and chemo-therapy, bi-specific antibodies therapy is rapidly adopted as a treatment.
End-user Outlook
The end-user segment of the bi-specific antibodies therapy market has been segregated into hospitals, specialty clinics, research institutions and others. Hospitals are rampantly adopting bi-specific antibody drug treatment and as they are more capable of treating several patients, they dominate in terms of market share.
Region Outlook
On the basis of region, North America bi-specific antibodies therapy market dominated in terms of market share in 2021. Many leading medical institutes, hospitals are present in countries like the United States and Canada which contribute to the growth of the health sector in the region. Meanwhile, the amount of awareness and capacity to pay is higher in patients.
Competitive Landscape
The report provides both, qualitative and quantitative research of global bi-specific antibodies therapy market as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contacts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the major players operating in the global bi-specific antibodies therapy market are listed below:
- Affimed GmbH
- Amgen Inc.
- AstraZeneca
- Biomunex
- Creative- Biolabs
- Emergent BioSolutions Inc.
- Hoffmann-La Roche Ltd
- F-star Therapeutics Inc.
- Genentech USA, Inc.
- Genmab A/S
- Johnson & Johnson
- MacroGenics, Inc.
- Merck KGaA
- Merus
- Pfizer Inc.
- Pieris
- Other Market Participants
Global Bi-Specific Antibodies Therapy Market
By Clinical Trials
- Preclinical
- Phase I
- Phase II
- Phase III
- Commercial
By Drug
- Blinatumomab
- Emicizumab
- Amivantamab-vmjw
- Mosunetuzumab
- Others
By Route of administration
- Intravenous
- Subcutaneous
By Application
- Cancer
- Autoimmune Diseases
- Infectious Diseases
- Neurologic Diseases
- Cardiovascular Diseases
- Others
By End-User
- Hospitals
- Specialty clinics
- Research Institutions
- Others
By Region
- North America
- U.S
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1.
Market
Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Historic Years: 2015 - 2021
1.2.2. Base Year: 2021
1.2.3. Forecast Years: 2022 – 2030
2.
Key
Target Audiences
3.
Research
Methodology
3.1. Primary Research
3.1.1. Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders
(KOLs)
3.2. Secondary Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4.
Recommendations
and Insights from AMI’s Perspective**
5.
Holistic
Overview of Bi-Specific Antibodies Therapy Market
6.
Market
Synopsis: Bi-Specific Antibodies Therapy
Market
7.
Bi-Specific
Antibodies Therapy Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.2.4. Challenges
7.3. Trends in Bi-Specific Antibodies Therapy
Market
7.4. Market Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic Indicators:
Bi-Specific Antibodies Therapy Market
7.6. Porter’s Five Force Analysis
7.7. Impact of Covid-19 on Bi-Specific Antibodies
Therapy Market
8.
Global
Bi-Specific Antibodies Therapy Market Analysis and Forecasts, 2022 – 2030
8.1. Overview
8.1.1. Global Bi-Specific Antibodies Therapy Market
Revenue (US$ Mn)
8.2. Global Bi-Specific Antibodies Therapy Market
Revenue (US$ Mn) and Forecasts, By Clinical Trials
8.2.1. Preclinical
8.2.1.1.
Definition
8.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.1.3.
Market
Forecast, 2022 – 2030
8.2.1.4.
Compound
Annual Growth Rate (CAGR)
8.2.1.5.
Regional
Bifurcation
8.2.1.5.1.
North
America
8.2.1.5.1.1. Market Estimation, 2015 - 2021
8.2.1.5.1.2. Market Forecast, 2022 – 2030
8.2.1.5.2.
Europe
8.2.1.5.2.1. Market Estimation, 2015 - 2021
8.2.1.5.2.2. Market Forecast, 2022 – 2030
8.2.1.5.3.
Asia
Pacific
8.2.1.5.3.1. Market Estimation, 2015 - 2021
8.2.1.5.3.2. Market Forecast, 2022 – 2030
8.2.1.5.4.
Middle
East and Africa
8.2.1.5.4.1. Market Estimation, 2015 - 2021
8.2.1.5.4.2. Market Forecast, 2022 – 2030
8.2.1.5.5.
Latin
America
8.2.1.5.5.1. Market Estimation, 2015 - 2021
8.2.1.5.5.2. Market Forecast, 2022 – 2030
8.2.2. Phase I
8.2.2.1.
Definition
8.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.2.3.
Market
Forecast, 2022 – 2030
8.2.2.4.
Compound
Annual Growth Rate (CAGR)
8.2.2.5.
Regional
Bifurcation
8.2.2.5.1.
North
America
8.2.2.5.1.1. Market Estimation, 2015 - 2021
8.2.2.5.1.2. Market Forecast, 2022 – 2030
8.2.2.5.2.
Europe
8.2.2.5.2.1. Market Estimation, 2015 - 2021
8.2.2.5.2.2. Market Forecast, 2022 – 2030
8.2.2.5.3.
Asia
Pacific
8.2.2.5.3.1. Market Estimation, 2015 - 2021
8.2.2.5.3.2. Market Forecast, 2022 – 2030
8.2.2.5.4.
Middle
East and Africa
8.2.2.5.4.1. Market Estimation, 2015 - 2021
8.2.2.5.4.2. Market Forecast, 2022 – 2030
8.2.2.5.5.
Latin
America
8.2.2.5.5.1. Market Estimation, 2015 - 2021
8.2.2.5.5.2. Market Forecast, 2022 – 2030
8.2.3. Phase II
8.2.3.1.
Definition
8.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.3.3.
Market
Forecast, 2022 – 2030
8.2.3.4.
Compound
Annual Growth Rate (CAGR)
8.2.3.5.
Regional
Bifurcation
8.2.3.5.1.
North
America
8.2.3.5.1.1. Market Estimation, 2015 - 2021
8.2.3.5.1.2. Market Forecast, 2022 – 2030
8.2.3.5.2.
Europe
8.2.3.5.2.1. Market Estimation, 2015 - 2021
8.2.3.5.2.2. Market Forecast, 2022 – 2030
8.2.3.5.3.
Asia
Pacific
8.2.3.5.3.1. Market Estimation, 2015 - 2021
8.2.3.5.3.2. Market Forecast, 2022 – 2030
8.2.3.5.4.
Middle
East and Africa
8.2.3.5.4.1. Market Estimation, 2015 - 2021
8.2.3.5.4.2. Market Forecast, 2022 – 2030
8.2.3.5.5.
Latin
America
8.2.3.5.5.1. Market Estimation, 2015 - 2021
8.2.3.5.5.2. Market Forecast, 2022 – 2030
8.2.4. Phase III
8.2.4.1.
Definition
8.2.4.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.4.3.
Market
Forecast, 2022 – 2030
8.2.4.4.
Compound
Annual Growth Rate (CAGR)
8.2.4.5.
Regional
Bifurcation
8.2.4.5.1.
North
America
8.2.4.5.1.1. Market Estimation, 2015 - 2021
8.2.4.5.1.2. Market Forecast, 2022 – 2030
8.2.4.5.2.
Europe
8.2.4.5.2.1. Market Estimation, 2015 - 2021
8.2.4.5.2.2. Market Forecast, 2022 – 2030
8.2.4.5.3.
Asia
Pacific
8.2.4.5.3.1. Market Estimation, 2015 - 2021
8.2.4.5.3.2. Market Forecast, 2022 – 2030
8.2.4.5.4.
Middle
East and Africa
8.2.4.5.4.1. Market Estimation, 2015 - 2021
8.2.4.5.4.2. Market Forecast, 2022 – 2030
8.2.4.5.5.
Latin
America
8.2.4.5.5.1. Market Estimation, 2015 - 2021
8.2.4.5.5.2. Market Forecast, 2022 – 2030
8.2.5. Commercial
8.2.5.1.
Definition
8.2.5.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.5.3.
Market
Forecast, 2022 – 2030
8.2.5.4.
Compound
Annual Growth Rate (CAGR)
8.2.5.5.
Regional
Bifurcation
8.2.5.5.1.
North
America
8.2.5.5.1.1. Market Estimation, 2015 - 2021
8.2.5.5.1.2. Market Forecast, 2022 – 2030
8.2.5.5.2.
Europe
8.2.5.5.2.1. Market Estimation, 2015 - 2021
8.2.5.5.2.2. Market Forecast, 2022 – 2030
8.2.5.5.3.
Asia
Pacific
8.2.5.5.3.1. Market Estimation, 2015 - 2021
8.2.5.5.3.2. Market Forecast, 2022 – 2030
8.2.5.5.4.
Middle
East and Africa
8.2.5.5.4.1. Market Estimation, 2015 - 2021
8.2.5.5.4.2. Market Forecast, 2022 – 2030
8.2.5.5.5.
Latin
America
8.2.5.5.5.1. Market Estimation, 2015 - 2021
8.2.5.5.5.2. Market Forecast, 2022 – 2030
8.3. Key Segment for Channeling Investments
8.3.1. By Clinical Trials
9.
Global
Bi-Specific Antibodies Therapy Market Analysis and Forecasts, 2022 – 2030
9.1. Overview
9.2. Global Bi-Specific Antibodies Therapy Market
Revenue (US$ Mn) and Forecasts, By Drug
9.2.1. Blinatumomab
9.2.1.1.
Definition
9.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.1.3.
Market
Forecast, 2022 – 2030
9.2.1.4.
Compound
Annual Growth Rate (CAGR)
9.2.1.5.
Regional
Bifurcation
9.2.1.5.1.
North
America
9.2.1.5.1.1. Market Estimation, 2015 - 2021
9.2.1.5.1.2. Market Forecast, 2022 – 2030
9.2.1.5.2.
Europe
9.2.1.5.2.1. Market Estimation, 2015 - 2021
9.2.1.5.2.2. Market Forecast, 2022 – 2030
9.2.1.5.3.
Asia
Pacific
9.2.1.5.3.1. Market Estimation, 2015 - 2021
9.2.1.5.3.2. Market Forecast, 2022 – 2030
9.2.1.5.4.
Middle
East and Africa
9.2.1.5.4.1. Market Estimation, 2015 - 2021
9.2.1.5.4.2. Market Forecast, 2022 – 2030
9.2.1.5.5.
Latin
America
9.2.1.5.5.1. Market Estimation, 2015 - 2021
9.2.1.5.5.2. Market Forecast, 2022 – 2030
9.2.2. Emicizumab
9.2.2.1.
Definition
9.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.2.3.
Market
Forecast, 2022 – 2030
9.2.2.4.
Compound
Annual Growth Rate (CAGR)
9.2.2.5.
Regional
Bifurcation
9.2.2.5.1.
North
America
9.2.2.5.1.1. Market Estimation, 2015 - 2021
9.2.2.5.1.2. Market Forecast, 2022 – 2030
9.2.2.5.2.
Europe
9.2.2.5.2.1. Market Estimation, 2015 - 2021
9.2.2.5.2.2. Market Forecast, 2022 – 2030
9.2.2.5.3.
Asia
Pacific
9.2.2.5.3.1. Market Estimation, 2015 - 2021
9.2.2.5.3.2. Market Forecast, 2022 – 2030
9.2.2.5.4.
Middle
East and Africa
9.2.2.5.4.1. Market Estimation, 2015 - 2021
9.2.2.5.4.2. Market Forecast, 2022 – 2030
9.2.2.5.5.
Latin
America
9.2.2.5.5.1. Market Estimation, 2015 - 2021
9.2.2.5.5.2. Market Forecast, 2022 – 2030
9.2.3. Amivantamab-vmjw
9.2.3.1.
Definition
9.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.3.3.
Market
Forecast, 2022 – 2030
9.2.3.4.
Compound
Annual Growth Rate (CAGR)
9.2.3.5.
Regional
Bifurcation
9.2.3.5.1.
North America
9.2.3.5.1.1. Market Estimation, 2015 - 2021
9.2.3.5.1.2. Market Forecast, 2022 – 2030
9.2.3.5.2.
Europe
9.2.3.5.2.1. Market Estimation, 2015 - 2021
9.2.3.5.2.2. Market Forecast, 2022 – 2030
9.2.3.5.3.
Asia
Pacific
9.2.3.5.3.1. Market Estimation, 2015 - 2021
9.2.3.5.3.2. Market Forecast, 2022 – 2030
9.2.3.5.4.
Middle
East and Africa
9.2.3.5.4.1. Market Estimation, 2015 - 2021
9.2.3.5.4.2. Market Forecast, 2022 – 2030
9.2.3.5.5.
Latin
America
9.2.3.5.5.1. Market Estimation, 2015 - 2021
9.2.3.5.5.2. Market Forecast, 2022 – 2030
9.2.4. Mosunetuzumab
9.2.4.1.
Definition
9.2.4.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.4.3.
Market
Forecast, 2022 – 2030
9.2.4.4.
Compound
Annual Growth Rate (CAGR)
9.2.4.5.
Regional
Bifurcation
9.2.4.5.1.
North
America
9.2.4.5.1.1. Market Estimation, 2015 - 2021
9.2.4.5.1.2. Market Forecast, 2022 – 2030
9.2.4.5.2.
Europe
9.2.4.5.2.1. Market Estimation, 2015 - 2021
9.2.4.5.2.2. Market Forecast, 2022 – 2030
9.2.4.5.3.
Asia
Pacific
9.2.4.5.3.1. Market Estimation, 2015 - 2021
9.2.4.5.3.2. Market Forecast, 2022 – 2030
9.2.4.5.4.
Middle
East and Africa
9.2.4.5.4.1. Market Estimation, 2015 - 2021
9.2.4.5.4.2. Market Forecast, 2022 – 2030
9.2.4.5.5.
Latin
America
9.2.4.5.5.1. Market Estimation, 2015 - 2021
9.2.4.5.5.2. Market Forecast, 2022 – 2030
9.2.5. Others
9.2.5.1.
Definition
9.2.5.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.5.3.
Market
Forecast, 2022 – 2030
9.2.5.4.
Compound
Annual Growth Rate (CAGR)
9.2.5.5.
Regional
Bifurcation
9.2.5.5.1.
North
America
9.2.5.5.1.1. Market Estimation, 2015 - 2021
9.2.5.5.1.2. Market Forecast, 2022 – 2030
9.2.5.5.2.
Europe
9.2.5.5.2.1. Market Estimation, 2015 - 2021
9.2.5.5.2.2. Market Forecast, 2022 – 2030
9.2.5.5.3.
Asia
Pacific
9.2.5.5.3.1. Market Estimation, 2015 - 2021
9.2.5.5.3.2. Market Forecast, 2022 – 2030
9.2.5.5.4.
Middle
East and Africa
9.2.5.5.4.1. Market Estimation, 2015 - 2021
9.2.5.5.4.2. Market Forecast, 2022 – 2030
9.2.5.5.5.
Latin
America
9.2.5.5.5.1. Market Estimation, 2015 - 2021
9.2.5.5.5.2. Market Forecast, 2022 – 2030
9.3. Key Segment for Channeling Investments
9.3.1. By Drug
10. Global Bi-Specific Antibodies Therapy Market
Analysis and Forecasts, 2022 – 2030
10.1. Overview
10.2. Global Bi-Specific Antibodies Therapy Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
10.2.1. Intravenous
10.2.1.1.
Definition
10.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.1.3.
Market
Forecast, 2022 – 2030
10.2.1.4.
Compound
Annual Growth Rate (CAGR)
10.2.1.5.
Regional
Bifurcation
10.2.1.5.1.
North
America
10.2.1.5.1.1. Market Estimation, 2015 - 2021
10.2.1.5.1.2. Market Forecast, 2022 – 2030
10.2.1.5.2.
Europe
10.2.1.5.2.1. Market Estimation, 2015 - 2021
10.2.1.5.2.2. Market Forecast, 2022 – 2030
10.2.1.5.3.
Asia
Pacific
10.2.1.5.3.1. Market Estimation, 2015 - 2021
10.2.1.5.3.2. Market Forecast, 2022 – 2030
10.2.1.5.4.
Middle
East and Africa
10.2.1.5.4.1. Market Estimation, 2015 - 2021
10.2.1.5.4.2. Market Forecast, 2022 – 2030
10.2.1.5.5.
Latin
America
10.2.1.5.5.1. Market Estimation, 2015 - 2021
10.2.1.5.5.2. Market Forecast, 2022 – 2030
10.2.2. Subcutaneous
10.2.2.1.
Definition
10.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.2.3.
Market
Forecast, 2022 – 2030
10.2.2.4.
Compound
Annual Growth Rate (CAGR)
10.2.2.5.
Regional
Bifurcation
10.2.2.5.1.
North
America
10.2.2.5.1.1. Market Estimation, 2015 - 2021
10.2.2.5.1.2. Market Forecast, 2022 – 2030
10.2.2.5.2.
Europe
10.2.2.5.2.1. Market Estimation, 2015 - 2021
10.2.2.5.2.2. Market Forecast, 2022 – 2030
10.2.2.5.3.
Asia
Pacific
10.2.2.5.3.1. Market Estimation, 2015 - 2021
10.2.2.5.3.2. Market Forecast, 2022 – 2030
10.2.2.5.4.
Middle
East and Africa
10.2.2.5.4.1. Market Estimation, 2015 - 2021
10.2.2.5.4.2. Market Forecast, 2022 – 2030
10.2.2.5.5.
Latin
America
10.2.2.5.5.1. Market Estimation, 2015 - 2021
10.2.2.5.5.2. Market Forecast, 2022 – 2030
10.3. Key Segment for Channeling Investments
10.3.1. By Route of Administration
11. Global Bi-Specific Antibodies Therapy Market
Analysis and Forecasts, 2022 – 2030
11.1. Overview
11.2. Global Bi-Specific Antibodies Therapy Market
Revenue (US$ Mn) and Forecasts, By Application
11.2.1. Cancer
11.2.1.1.
Definition
11.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.1.3.
Market
Forecast, 2022 – 2030
11.2.1.4.
Compound
Annual Growth Rate (CAGR)
11.2.1.5.
Regional
Bifurcation
11.2.1.5.1.
North
America
11.2.1.5.1.1. Market Estimation, 2015 - 2021
11.2.1.5.1.2. Market Forecast, 2022 – 2030
11.2.1.5.2.
Europe
11.2.1.5.2.1. Market Estimation, 2015 - 2021
11.2.1.5.2.2. Market Forecast, 2022 – 2030
11.2.1.5.3.
Asia
Pacific
11.2.1.5.3.1. Market Estimation, 2015 - 2021
11.2.1.5.3.2. Market Forecast, 2022 – 2030
11.2.1.5.4.
Middle
East and Africa
11.2.1.5.4.1. Market Estimation, 2015 - 2021
11.2.1.5.4.2. Market Forecast, 2022 – 2030
11.2.1.5.5.
Latin
America
11.2.1.5.5.1. Market Estimation, 2015 - 2021
11.2.1.5.5.2. Market Forecast, 2022 – 2030
11.2.2. Autoimmune Diseases
11.2.2.1.
Definition
11.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.2.3.
Market
Forecast, 2022 – 2030
11.2.2.4.
Compound
Annual Growth Rate (CAGR)
11.2.2.5.
Regional
Bifurcation
11.2.2.5.1.
North
America
11.2.2.5.1.1. Market Estimation, 2015 - 2021
11.2.2.5.1.2. Market Forecast, 2022 – 2030
11.2.2.5.2.
Europe
11.2.2.5.2.1. Market Estimation, 2015 - 2021
11.2.2.5.2.2. Market Forecast, 2022 – 2030
11.2.2.5.3.
Asia
Pacific
11.2.2.5.3.1. Market Estimation, 2015 - 2021
11.2.2.5.3.2. Market Forecast, 2022 – 2030
11.2.2.5.4.
Middle
East and Africa
11.2.2.5.4.1. Market Estimation, 2015 - 2021
11.2.2.5.4.2. Market Forecast, 2022 – 2030
11.2.2.5.5.
Latin
America
11.2.2.5.5.1. Market Estimation, 2015 - 2021
11.2.2.5.5.2. Market Forecast, 2022 – 2030
11.2.3. Infectious Diseases
11.2.3.1.
Definition
11.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.3.3.
Market
Forecast, 2022 – 2030
11.2.3.4.
Compound
Annual Growth Rate (CAGR)
11.2.3.5.
Regional
Bifurcation
11.2.3.5.1.
North
America
11.2.3.5.1.1. Market Estimation, 2015 - 2021
11.2.3.5.1.2. Market Forecast, 2022 – 2030
11.2.3.5.2.
Europe
11.2.3.5.2.1. Market Estimation, 2015 - 2021
11.2.3.5.2.2. Market Forecast, 2022 – 2030
11.2.3.5.3.
Asia
Pacific
11.2.3.5.3.1. Market Estimation, 2015 - 2021
11.2.3.5.3.2. Market Forecast, 2022 – 2030
11.2.3.5.4.
Middle
East and Africa
11.2.3.5.4.1. Market Estimation, 2015 - 2021
11.2.3.5.4.2. Market Forecast, 2022 – 2030
11.2.3.5.5.
Latin
America
11.2.3.5.5.1. Market Estimation, 2015 - 2021
11.2.3.5.5.2. Market Forecast, 2022 – 2030
11.2.4. Neurologic Diseases
11.2.4.1.
Definition
11.2.4.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.4.3.
Market
Forecast, 2022 – 2030
11.2.4.4.
Compound
Annual Growth Rate (CAGR)
11.2.4.5.
Regional
Bifurcation
11.2.4.5.1.
North
America
11.2.4.5.1.1. Market Estimation, 2015 - 2021
11.2.4.5.1.2. Market Forecast, 2022 – 2030
11.2.4.5.2.
Europe
11.2.4.5.2.1. Market Estimation, 2015 - 2021
11.2.4.5.2.2. Market Forecast, 2022 – 2030
11.2.4.5.3.
Asia
Pacific
11.2.4.5.3.1. Market Estimation, 2015 - 2021
11.2.4.5.3.2. Market Forecast, 2022 – 2030
11.2.4.5.4.
Middle
East and Africa
11.2.4.5.4.1. Market Estimation, 2015 - 2021
11.2.4.5.4.2. Market Forecast, 2022 – 2030
11.2.4.5.5.
Latin
America
11.2.4.5.5.1. Market Estimation, 2015 - 2021
11.2.4.5.5.2. Market Forecast, 2022 – 2030
11.2.5. Cardiovascular Diseases
11.2.5.1.
Definition
11.2.5.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.5.3.
Market
Forecast, 2022 – 2030
11.2.5.4.
Compound
Annual Growth Rate (CAGR)
11.2.5.5.
Regional
Bifurcation
11.2.5.5.1.
North
America
11.2.5.5.1.1. Market Estimation, 2015 - 2021
11.2.5.5.1.2. Market Forecast, 2022 – 2030
11.2.5.5.2.
Europe
11.2.5.5.2.1. Market Estimation, 2015 - 2021
11.2.5.5.2.2. Market Forecast, 2022 – 2030
11.2.5.5.3.
Asia
Pacific
11.2.5.5.3.1. Market Estimation, 2015 - 2021
11.2.5.5.3.2. Market Forecast, 2022 – 2030
11.2.5.5.4.
Middle
East and Africa
11.2.5.5.4.1. Market Estimation, 2015 - 2021
11.2.5.5.4.2. Market Forecast, 2022 – 2030
11.2.5.5.5.
Latin
America
11.2.5.5.5.1. Market Estimation, 2015 - 2021
11.2.5.5.5.2. Market Forecast, 2022 – 2030
11.2.6. Others
11.2.6.1.
Definition
11.2.6.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.6.3.
Market
Forecast, 2022 – 2030
11.2.6.4.
Compound
Annual Growth Rate (CAGR)
11.2.6.5.
Regional
Bifurcation
11.2.6.5.1.
North
America
11.2.6.5.1.1. Market Estimation, 2015 - 2021
11.2.6.5.1.2. Market Forecast, 2022 – 2030
11.2.6.5.2.
Europe
11.2.6.5.2.1. Market Estimation, 2015 - 2021
11.2.6.5.2.2. Market Forecast, 2022 – 2030
11.2.6.5.3.
Asia
Pacific
11.2.6.5.3.1. Market Estimation, 2015 - 2021
11.2.6.5.3.2. Market Forecast, 2022 – 2030
11.2.6.5.4.
Middle
East and Africa
11.2.6.5.4.1. Market Estimation, 2015 - 2021
11.2.6.5.4.2. Market Forecast, 2022 – 2030
11.2.6.5.5.
Latin
America
11.2.6.5.5.1. Market Estimation, 2015 - 2021
11.2.6.5.5.2. Market Forecast, 2022 – 2030
11.3. Key Segment for Channeling Investments
11.3.1. By Application
12. Global Bi-Specific Antibodies Therapy Market
Analysis and Forecasts, 2022 – 2030
12.1. Overview
12.2. Global Bi-Specific Antibodies Therapy Market
Revenue (US$ Mn) and Forecasts, By End-User
12.2.1. Hospitals
12.2.1.1.
Definition
12.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
12.2.1.3.
Market
Forecast, 2022 – 2030
12.2.1.4.
Compound
Annual Growth Rate (CAGR)
12.2.1.5.
Regional
Bifurcation
12.2.1.5.1.
North
America
12.2.1.5.1.1. Market Estimation, 2015 - 2021
12.2.1.5.1.2. Market Forecast, 2022 – 2030
12.2.1.5.2.
Europe
12.2.1.5.2.1. Market Estimation, 2015 - 2021
12.2.1.5.2.2. Market Forecast, 2022 – 2030
12.2.1.5.3.
Asia
Pacific
12.2.1.5.3.1. Market Estimation, 2015 - 2021
12.2.1.5.3.2. Market Forecast, 2022 – 2030
12.2.1.5.4.
Middle
East and Africa
12.2.1.5.4.1. Market Estimation, 2015 - 2021
12.2.1.5.4.2. Market Forecast, 2022 – 2030
12.2.1.5.5.
Latin
America
12.2.1.5.5.1. Market Estimation, 2015 - 2021
12.2.1.5.5.2. Market Forecast, 2022 – 2030
12.2.2. Specialty clinics
12.2.2.1.
Definition
12.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
12.2.2.3.
Market
Forecast, 2022 – 2030
12.2.2.4.
Compound
Annual Growth Rate (CAGR)
12.2.2.5.
Regional
Bifurcation
12.2.2.5.1.
North
America
12.2.2.5.1.1. Market Estimation, 2015 - 2021
12.2.2.5.1.2. Market Forecast, 2022 – 2030
12.2.2.5.2.
Europe
12.2.2.5.2.1. Market Estimation, 2015 - 2021
12.2.2.5.2.2. Market Forecast, 2022 – 2030
12.2.2.5.3.
Asia
Pacific
12.2.2.5.3.1. Market Estimation, 2015 - 2021
12.2.2.5.3.2. Market Forecast, 2022 – 2030
12.2.2.5.4.
Middle
East and Africa
12.2.2.5.4.1. Market Estimation, 2015 - 2021
12.2.2.5.4.2. Market Forecast, 2022 – 2030
12.2.2.5.5.
Latin
America
12.2.2.5.5.1. Market Estimation, 2015 - 2021
12.2.2.5.5.2. Market Forecast, 2022 – 2030
12.2.3. Research Institutions
12.2.3.1.
Definition
12.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
12.2.3.3.
Market
Forecast, 2022 – 2030
12.2.3.4.
Compound
Annual Growth Rate (CAGR)
12.2.3.5.
Regional
Bifurcation
12.2.3.5.1.
North
America
12.2.3.5.1.1. Market Estimation, 2015 - 2021
12.2.3.5.1.2. Market Forecast, 2022 – 2030
12.2.3.5.2.
Europe
12.2.3.5.2.1. Market Estimation, 2015 - 2021
12.2.3.5.2.2. Market Forecast, 2022 – 2030
12.2.3.5.3.
Asia
Pacific
12.2.3.5.3.1. Market Estimation, 2015 - 2021
12.2.3.5.3.2. Market Forecast, 2022 – 2030
12.2.3.5.4.
Middle
East and Africa
12.2.3.5.4.1. Market Estimation, 2015 - 2021
12.2.3.5.4.2. Market Forecast, 2022 – 2030
12.2.3.5.5.
Latin
America
12.2.3.5.5.1. Market Estimation, 2015 - 2021
12.2.3.5.5.2. Market Forecast, 2022 – 2030
12.2.4. Others
12.2.4.1.
Definition
12.2.4.2.
Market
Estimation and Penetration, 2015 - 2021
12.2.4.3.
Market
Forecast, 2022 – 2030
12.2.4.4.
Compound
Annual Growth Rate (CAGR)
12.2.4.5.
Regional
Bifurcation
12.2.4.5.1.
North
America
12.2.4.5.1.1. Market Estimation, 2015 - 2021
12.2.4.5.1.2. Market Forecast, 2022 – 2030
12.2.4.5.2.
Europe
12.2.4.5.2.1. Market Estimation, 2015 - 2021
12.2.4.5.2.2. Market Forecast, 2022 – 2030
12.2.4.5.3.
Asia
Pacific
12.2.4.5.3.1. Market Estimation, 2015 - 2021
12.2.4.5.3.2. Market Forecast, 2022 – 2030
12.2.4.5.4.
Middle
East and Africa
12.2.4.5.4.1. Market Estimation, 2015 - 2021
12.2.4.5.4.2. Market Forecast, 2022 – 2030
12.2.4.5.5.
Latin
America
12.2.4.5.5.1. Market Estimation, 2015 - 2021
12.2.4.5.5.2. Market Forecast, 2022 – 2030
12.3. Key Segment for Channeling Investments
12.3.1. By End-User
13. North America Bi-Specific Antibodies Therapy
Market Analysis and Forecasts, 2022 – 2030
13.1. Overview
13.1.1. North America Bi-Specific Antibodies Therapy
Market Revenue (US$ Mn)
13.2. North America Bi-Specific Antibodies Therapy
Market Revenue (US$ Mn) and Forecasts, By Clinical Trials
13.2.1. Preclinical
13.2.2. Phase I
13.2.3. Phase II
13.2.4. Phase III
13.2.5. Commercial
13.3. North America Bi-Specific Antibodies Therapy
Market Revenue (US$ Mn) and Forecasts, By Drug
13.3.1. Blinatumomab
13.3.2. Emicizumab
13.3.3. Amivantamab-vmjw
13.3.4. Mosunetuzumab
13.3.5. Others
13.4. North America Bi-Specific Antibodies Therapy
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
13.4.1. Intravenous
13.4.2. Subcutaneous
13.5. North America Bi-Specific Antibodies Therapy
Market Revenue (US$ Mn) and Forecasts, By Application
13.5.1. Cancer
13.5.2. Autoimmune Diseases
13.5.3. Infectious Diseases
13.5.4. Neurologic Diseases
13.5.5. Cardiovascular Diseases
13.5.6. Others
13.6. North America Bi-Specific Antibodies Therapy
Market Revenue (US$ Mn) and Forecasts, By End-User
13.6.1. Hospitals
13.6.2. Specialty clinics
13.6.3. Research Institutions
13.6.4. Others
13.7. North America Bi-Specific Antibodies Therapy
Market Revenue (US$ Mn) and Forecasts, By Country
13.7.1. U.S
13.7.1.1.
U.S
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Clinical Trials
13.7.1.1.1.
Preclinical
13.7.1.1.2.
Phase I
13.7.1.1.3.
Phase II
13.7.1.1.4.
Phase
III
13.7.1.1.5.
Commercial
13.7.1.2.
U.S
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By Drug
13.7.1.2.1.
Blinatumomab
13.7.1.2.2.
Emicizumab
13.7.1.2.3.
Amivantamab-vmjw
13.7.1.2.4.
Mosunetuzumab
13.7.1.2.5.
Others
13.7.1.3.
U.S
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
13.7.1.3.1.
Intravenous
13.7.1.3.2.
Subcutaneous
13.7.1.4.
U.S
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Application
13.7.1.4.1.
Cancer
13.7.1.4.2.
Autoimmune
Diseases
13.7.1.4.3.
Infectious
Diseases
13.7.1.4.4.
Neurologic
Diseases
13.7.1.4.5.
Cardiovascular
Diseases
13.7.1.4.6.
Others
13.7.1.5.
U.S
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
End-User
13.7.1.5.1.
Hospitals
13.7.1.5.2.
Specialty
clinics
13.7.1.5.3.
Research
Institutions
13.7.1.5.4.
Others
13.7.2. Canada
13.7.2.1.
Canada
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Clinical Trials
13.7.2.1.1.
Preclinical
13.7.2.1.2.
Phase I
13.7.2.1.3.
Phase II
13.7.2.1.4.
Phase
III
13.7.2.1.5.
Commercial
13.7.2.2.
Canada
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By Drug
13.7.2.2.1.
Blinatumomab
13.7.2.2.2.
Emicizumab
13.7.2.2.3.
Amivantamab-vmjw
13.7.2.2.4.
Mosunetuzumab
13.7.2.2.5.
Others
13.7.2.3.
Canada
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
13.7.2.3.1.
Intravenous
13.7.2.3.2.
Subcutaneous
13.7.2.4.
Canada
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Application
13.7.2.4.1.
Cancer
13.7.2.4.2.
Autoimmune
Diseases
13.7.2.4.3.
Infectious
Diseases
13.7.2.4.4.
Neurologic
Diseases
13.7.2.4.5.
Cardiovascular
Diseases
13.7.2.4.6.
Others
13.7.2.5.
Canada
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
End-User
13.7.2.5.1.
Hospitals
13.7.2.5.2.
Specialty
clinics
13.7.2.5.3.
Research
Institutions
13.7.2.5.4.
Others
13.7.3. Mexico
13.7.3.1.
Mexico
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Clinical Trials
13.7.3.1.1.
Preclinical
13.7.3.1.2.
Phase I
13.7.3.1.3.
Phase II
13.7.3.1.4.
Phase
III
13.7.3.1.5.
Commercial
13.7.3.2.
Mexico
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By Drug
13.7.3.2.1.
Blinatumomab
13.7.3.2.2.
Emicizumab
13.7.3.2.3.
Amivantamab-vmjw
13.7.3.2.4.
Mosunetuzumab
13.7.3.2.5.
Others
13.7.3.3.
Mexico
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
13.7.3.3.1.
Intravenous
13.7.3.3.2.
Subcutaneous
13.7.3.4.
Mexico
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Application
13.7.3.4.1.
Cancer
13.7.3.4.2.
Autoimmune
Diseases
13.7.3.4.3.
Infectious
Diseases
13.7.3.4.4.
Neurologic
Diseases
13.7.3.4.5.
Cardiovascular
Diseases
13.7.3.4.6.
Others
13.7.3.5.
Mexico
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
End-User
13.7.3.5.1.
Hospitals
13.7.3.5.2.
Specialty
clinics
13.7.3.5.3.
Research
Institutions
13.7.3.5.4.
Others
13.7.4. Rest of North America
13.7.4.1.
Rest of
North America Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts,
By Clinical Trials
13.7.4.1.1.
Preclinical
13.7.4.1.2.
Phase I
13.7.4.1.3.
Phase II
13.7.4.1.4.
Phase
III
13.7.4.1.5.
Commercial
13.7.4.2.
Rest of
North America Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and
Forecasts, By Drug
13.7.4.2.1.
Blinatumomab
13.7.4.2.2.
Emicizumab
13.7.4.2.3.
Amivantamab-vmjw
13.7.4.2.4.
Mosunetuzumab
13.7.4.2.5.
Others
13.7.4.3.
Rest of
North America Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
13.7.4.3.1.
Intravenous
13.7.4.3.2.
Subcutaneous
13.7.4.4.
Rest of
North America Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and
Forecasts, By Application
13.7.4.4.1.
Cancer
13.7.4.4.2.
Autoimmune
Diseases
13.7.4.4.3.
Infectious
Diseases
13.7.4.4.4.
Neurologic
Diseases
13.7.4.4.5.
Cardiovascular
Diseases
13.7.4.4.6.
Others
13.7.4.5.
Rest of
North America Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and
Forecasts, By End-User
13.7.4.5.1.
Hospitals
13.7.4.5.2.
Specialty
clinics
13.7.4.5.3.
Research
Institutions
13.7.4.5.4.
Others
13.8. Key Segment for Channeling Investments
13.8.1. By Country
13.8.2. By Clinical Trials
13.8.3. By Drug
13.8.4. By Route of Administration
13.8.5. By Application
13.8.6. By End-User
14. Europe Bi-Specific Antibodies Therapy Market
Analysis and Forecasts, 2022 – 2030
14.1. Overview
14.1.1. Europe Bi-Specific Antibodies Therapy Market
Revenue (US$ Mn)
14.2. Europe Bi-Specific Antibodies Therapy Market
Revenue (US$ Mn) and Forecasts, By Clinical Trials
14.2.1. Preclinical
14.2.2. Phase I
14.2.3. Phase II
14.2.4. Phase III
14.2.5. Commercial
14.3. Europe Bi-Specific Antibodies Therapy Market
Revenue (US$ Mn) and Forecasts, By Drug
14.3.1. Blinatumomab
14.3.2. Emicizumab
14.3.3. Amivantamab-vmjw
14.3.4. Mosunetuzumab
14.3.5. Others
14.4. Europe Bi-Specific Antibodies Therapy Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
14.4.1. Intravenous
14.4.2. Subcutaneous
14.5. Europe Bi-Specific Antibodies Therapy Market
Revenue (US$ Mn) and Forecasts, By Application
14.5.1. Cancer
14.5.2. Autoimmune Diseases
14.5.3. Infectious Diseases
14.5.4. Neurologic Diseases
14.5.5. Cardiovascular Diseases
14.5.6. Others
14.6. Europe Bi-Specific Antibodies Therapy Market
Revenue (US$ Mn) and Forecasts, By End-User
14.6.1. Hospitals
14.6.2. Specialty clinics
14.6.3. Research Institutions
14.6.4. Others
14.7. Europe Bi-Specific Antibodies Therapy Market
Revenue (US$ Mn) and Forecasts, By Country
14.7.1. France
14.7.1.1.
France
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Clinical Trials
14.7.1.1.1.
Preclinical
14.7.1.1.2.
Phase I
14.7.1.1.3.
Phase II
14.7.1.1.4.
Phase
III
14.7.1.1.5.
Commercial
14.7.1.2.
France
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By Drug
14.7.1.2.1.
Blinatumomab
14.7.1.2.2.
Emicizumab
14.7.1.2.3.
Amivantamab-vmjw
14.7.1.2.4.
Mosunetuzumab
14.7.1.2.5.
Others
14.7.1.3.
France
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
14.7.1.3.1.
Intravenous
14.7.1.3.2.
Subcutaneous
14.7.1.4.
France
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Application
14.7.1.4.1.
Cancer
14.7.1.4.2.
Autoimmune
Diseases
14.7.1.4.3.
Infectious
Diseases
14.7.1.4.4.
Neurologic
Diseases
14.7.1.4.5.
Cardiovascular
Diseases
14.7.1.4.6.
Others
14.7.1.5.
France
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
End-User
14.7.1.5.1.
Hospitals
14.7.1.5.2.
Specialty
clinics
14.7.1.5.3.
Research
Institutions
14.7.1.5.4.
Others
14.7.2. The UK
14.7.2.1.
The UK
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Clinical Trials
14.7.2.1.1.
Preclinical
14.7.2.1.2.
Phase I
14.7.2.1.3.
Phase II
14.7.2.1.4.
Phase
III
14.7.2.1.5.
Commercial
14.7.2.2.
The UK Bi-Specific
Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By Drug
14.7.2.2.1.
Blinatumomab
14.7.2.2.2.
Emicizumab
14.7.2.2.3.
Amivantamab-vmjw
14.7.2.2.4.
Mosunetuzumab
14.7.2.2.5.
Others
14.7.2.3.
The UK
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
14.7.2.3.1.
Intravenous
14.7.2.3.2.
Subcutaneous
14.7.2.4.
The UK
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Application
14.7.2.4.1.
Cancer
14.7.2.4.2.
Autoimmune
Diseases
14.7.2.4.3.
Infectious
Diseases
14.7.2.4.4.
Neurologic
Diseases
14.7.2.4.5.
Cardiovascular
Diseases
14.7.2.4.6.
Others
14.7.2.5.
The UK
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
End-User
14.7.2.5.1.
Hospitals
14.7.2.5.2.
Specialty
clinics
14.7.2.5.3.
Research
Institutions
14.7.2.5.4.
Others
14.7.3. Spain
14.7.3.1.
Spain
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Clinical Trials
14.7.3.1.1.
Preclinical
14.7.3.1.2.
Phase I
14.7.3.1.3.
Phase II
14.7.3.1.4.
Phase
III
14.7.3.1.5.
Commercial
14.7.3.2.
Spain
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By Drug
14.7.3.2.1.
Blinatumomab
14.7.3.2.2.
Emicizumab
14.7.3.2.3.
Amivantamab-vmjw
14.7.3.2.4.
Mosunetuzumab
14.7.3.2.5.
Others
14.7.3.3.
Spain
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
14.7.3.3.1.
Intravenous
14.7.3.3.2.
Subcutaneous
14.7.3.4.
Spain
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Application
14.7.3.4.1.
Cancer
14.7.3.4.2.
Autoimmune
Diseases
14.7.3.4.3.
Infectious
Diseases
14.7.3.4.4.
Neurologic
Diseases
14.7.3.4.5.
Cardiovascular
Diseases
14.7.3.4.6.
Others
14.7.3.5.
Spain
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
End-User
14.7.3.5.1.
Hospitals
14.7.3.5.2.
Specialty
clinics
14.7.3.5.3.
Research
Institutions
14.7.3.5.4.
Others
14.7.4. Germany
14.7.4.1.
Germany
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Clinical Trials
14.7.4.1.1.
Preclinical
14.7.4.1.2.
Phase I
14.7.4.1.3.
Phase II
14.7.4.1.4.
Phase
III
14.7.4.1.5.
Commercial
14.7.4.2.
Germany Bi-Specific
Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By Drug
14.7.4.2.1.
Blinatumomab
14.7.4.2.2.
Emicizumab
14.7.4.2.3.
Amivantamab-vmjw
14.7.4.2.4.
Mosunetuzumab
14.7.4.2.5.
Others
14.7.4.3.
Germany
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
14.7.4.3.1.
Intravenous
14.7.4.3.2.
Subcutaneous
14.7.4.4.
Germany
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Application
14.7.4.4.1.
Cancer
14.7.4.4.2.
Autoimmune
Diseases
14.7.4.4.3.
Infectious
Diseases
14.7.4.4.4.
Neurologic
Diseases
14.7.4.4.5.
Cardiovascular
Diseases
14.7.4.4.6.
Others
14.7.4.5.
Germany
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
End-User
14.7.4.5.1.
Hospitals
14.7.4.5.2.
Specialty
clinics
14.7.4.5.3.
Research
Institutions
14.7.4.5.4.
Others
14.7.5. Italy
14.7.5.1.
Italy
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Clinical Trials
14.7.5.1.1.
Preclinical
14.7.5.1.2.
Phase I
14.7.5.1.3.
Phase II
14.7.5.1.4.
Phase
III
14.7.5.1.5.
Commercial
14.7.5.2.
Italy
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By Drug
14.7.5.2.1.
Blinatumomab
14.7.5.2.2.
Emicizumab
14.7.5.2.3.
Amivantamab-vmjw
14.7.5.2.4.
Mosunetuzumab
14.7.5.2.5.
Others
14.7.5.3.
Italy
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
14.7.5.3.1.
Intravenous
14.7.5.3.2.
Subcutaneous
14.7.5.4.
Italy
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Application
14.7.5.4.1.
Cancer
14.7.5.4.2.
Autoimmune
Diseases
14.7.5.4.3.
Infectious
Diseases
14.7.5.4.4.
Neurologic
Diseases
14.7.5.4.5.
Cardiovascular
Diseases
14.7.5.4.6.
Others
14.7.5.5.
Italy
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
End-User
14.7.5.5.1.
Hospitals
14.7.5.5.2.
Specialty
clinics
14.7.5.5.3.
Research
Institutions
14.7.5.5.4.
Others
14.7.6. Nordic Countries
14.7.6.1.
Nordic
Countries Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts,
By Clinical Trials
14.7.6.1.1.
Preclinical
14.7.6.1.2.
Phase I
14.7.6.1.3.
Phase II
14.7.6.1.4.
Phase
III
14.7.6.1.5.
Commercial
14.7.6.2.
Nordic
Countries Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts,
By Drug
14.7.6.2.1.
Blinatumomab
14.7.6.2.2.
Emicizumab
14.7.6.2.3.
Amivantamab-vmjw
14.7.6.2.4.
Mosunetuzumab
14.7.6.2.5.
Others
14.7.6.3.
Nordic
Countries Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts,
By Route of Administration
14.7.6.3.1.
Intravenous
14.7.6.3.2.
Subcutaneous
14.7.6.4.
Nordic
Countries Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts,
By Application
14.7.6.4.1.
Cancer
14.7.6.4.2.
Autoimmune
Diseases
14.7.6.4.3.
Infectious
Diseases
14.7.6.4.4.
Neurologic
Diseases
14.7.6.4.5.
Cardiovascular
Diseases
14.7.6.4.6.
Others
14.7.6.5.
Nordic
Countries Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts,
By End-User
14.7.6.5.1.
Hospitals
14.7.6.5.2.
Specialty
clinics
14.7.6.5.3.
Research
Institutions
14.7.6.5.4.
Others
14.7.6.6.
Nordic
Countries Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts,
By Country
14.7.6.6.1.
Denmark
14.7.6.6.2.
Finland
14.7.6.6.3.
Iceland
14.7.6.6.4.
Sweden
14.7.6.6.5.
Norway
14.7.7. Benelux Union
14.7.7.1.
Benelux
Union Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Clinical Trials
14.7.7.1.1.
Preclinical
14.7.7.1.2.
Phase I
14.7.7.1.3.
Phase II
14.7.7.1.4.
Phase
III
14.7.7.1.5.
Commercial
14.7.7.2.
Benelux
Union Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Drug
14.7.7.2.1.
Blinatumomab
14.7.7.2.2.
Emicizumab
14.7.7.2.3.
Amivantamab-vmjw
14.7.7.2.4.
Mosunetuzumab
14.7.7.2.5.
Others
14.7.7.3.
Benelux
Union Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
14.7.7.3.1.
Intravenous
14.7.7.3.2.
Subcutaneous
14.7.7.4.
Benelux
Union Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Application
14.7.7.4.1.
Cancer
14.7.7.4.2.
Autoimmune
Diseases
14.7.7.4.3.
Infectious
Diseases
14.7.7.4.4.
Neurologic
Diseases
14.7.7.4.5.
Cardiovascular
Diseases
14.7.7.4.6.
Others
14.7.7.5.
Benelux
Union Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
End-User
14.7.7.5.1.
Hospitals
14.7.7.5.2.
Specialty
clinics
14.7.7.5.3.
Research
Institutions
14.7.7.5.4.
Others
14.7.7.6.
Benelux
Union Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Country
14.7.7.6.1.
Belgium
14.7.7.6.2.
The
Netherlands
14.7.7.6.3.
Luxembourg
14.7.8. Rest of Europe
14.7.8.1.
Rest of
Europe Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Clinical Trials
14.7.8.1.1.
Preclinical
14.7.8.1.2.
Phase I
14.7.8.1.3.
Phase II
14.7.8.1.4.
Phase
III
14.7.8.1.5.
Commercial
14.7.8.2.
Rest of
Europe Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Drug
14.7.8.2.1.
Blinatumomab
14.7.8.2.2.
Emicizumab
14.7.8.2.3.
Amivantamab-vmjw
14.7.8.2.4.
Mosunetuzumab
14.7.8.2.5.
Others
14.7.8.3.
Rest of
Europe Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
14.7.8.3.1.
Intravenous
14.7.8.3.2.
Subcutaneous
14.7.8.4.
Rest of
Europe Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Application
14.7.8.4.1.
Cancer
14.7.8.4.2.
Autoimmune
Diseases
14.7.8.4.3.
Infectious
Diseases
14.7.8.4.4.
Neurologic
Diseases
14.7.8.4.5.
Cardiovascular
Diseases
14.7.8.4.6.
Others
14.7.8.5.
Rest of
Europe Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
End-User
14.7.8.5.1.
Hospitals
14.7.8.5.2.
Specialty
clinics
14.7.8.5.3.
Research
Institutions
14.7.8.5.4.
Others
14.8. Key Segment for Channeling Investments
14.8.1. By Country
14.8.2. By Clinical Trials
14.8.3. By Drug
14.8.4. By Route of Administration
14.8.5. By Application
14.8.6. By End-User
15. Asia Pacific Bi-Specific Antibodies Therapy
Market Analysis and Forecasts, 2022 – 2030
15.1. Overview
15.1.1. Asia Pacific Bi-Specific Antibodies Therapy
Market Revenue (US$ Mn)
15.2. Asia Pacific Bi-Specific Antibodies Therapy
Market Revenue (US$ Mn) and Forecasts, By Clinical Trials
15.2.1. Preclinical
15.2.2. Phase I
15.2.3. Phase II
15.2.4. Phase III
15.2.5. Commercial
15.3. Asia Pacific Bi-Specific Antibodies Therapy
Market Revenue (US$ Mn) and Forecasts, By Drug
15.3.1. Blinatumomab
15.3.2. Emicizumab
15.3.3. Amivantamab-vmjw
15.3.4. Mosunetuzumab
15.3.5. Others
15.4. Asia Pacific Bi-Specific Antibodies Therapy
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
15.4.1. Intravenous
15.4.2. Subcutaneous
15.5. Asia Pacific Bi-Specific Antibodies Therapy
Market Revenue (US$ Mn) and Forecasts, By Application
15.5.1. Cancer
15.5.2. Autoimmune Diseases
15.5.3. Infectious Diseases
15.5.4. Neurologic Diseases
15.5.5. Cardiovascular Diseases
15.5.6. Others
15.6. Asia Pacific Bi-Specific Antibodies Therapy
Market Revenue (US$ Mn) and Forecasts, By End-User
15.6.1. Hospitals
15.6.2. Specialty clinics
15.6.3. Research Institutions
15.6.4. Others
15.7. Asia Pacific Bi-Specific Antibodies Therapy
Market Revenue (US$ Mn) and Forecasts, By Country
15.7.1. China
15.7.1.1.
China
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Clinical Trials
15.7.1.1.1.
Preclinical
15.7.1.1.2.
Phase I
15.7.1.1.3.
Phase II
15.7.1.1.4.
Phase
III
15.7.1.1.5.
Commercial
15.7.1.2.
China
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By Drug
15.7.1.2.1.
Blinatumomab
15.7.1.2.2.
Emicizumab
15.7.1.2.3.
Amivantamab-vmjw
15.7.1.2.4.
Mosunetuzumab
15.7.1.2.5.
Others
15.7.1.3.
China
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
15.7.1.3.1.
Intravenous
15.7.1.3.2.
Subcutaneous
15.7.1.4.
China
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Application
15.7.1.4.1.
Cancer
15.7.1.4.2.
Autoimmune
Diseases
15.7.1.4.3.
Infectious
Diseases
15.7.1.4.4.
Neurologic
Diseases
15.7.1.4.5.
Cardiovascular
Diseases
15.7.1.4.6.
Others
15.7.1.5.
China
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
End-User
15.7.1.5.1.
Hospitals
15.7.1.5.2.
Specialty
clinics
15.7.1.5.3.
Research
Institutions
15.7.1.5.4.
Others
15.7.2. Japan
15.7.2.1.
Japan
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Clinical Trials
15.7.2.1.1.
Preclinical
15.7.2.1.2.
Phase I
15.7.2.1.3.
Phase II
15.7.2.1.4.
Phase
III
15.7.2.1.5.
Commercial
15.7.2.2.
Japan
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By Drug
15.7.2.2.1.
Blinatumomab
15.7.2.2.2.
Emicizumab
15.7.2.2.3.
Amivantamab-vmjw
15.7.2.2.4.
Mosunetuzumab
15.7.2.2.5.
Others
15.7.2.3.
Japan
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
15.7.2.3.1.
Intravenous
15.7.2.3.2.
Subcutaneous
15.7.2.4.
Japan
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Application
15.7.2.4.1.
Cancer
15.7.2.4.2.
Autoimmune
Diseases
15.7.2.4.3.
Infectious
Diseases
15.7.2.4.4.
Neurologic
Diseases
15.7.2.4.5.
Cardiovascular
Diseases
15.7.2.4.6.
Others
15.7.2.5.
Japan
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
End-User
15.7.2.5.1.
Hospitals
15.7.2.5.2.
Specialty
clinics
15.7.2.5.3.
Research
Institutions
15.7.2.5.4.
Others
15.7.3. India
15.7.3.1.
India
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Clinical Trials
15.7.3.1.1.
Preclinical
15.7.3.1.2.
Phase I
15.7.3.1.3.
Phase II
15.7.3.1.4.
Phase
III
15.7.3.1.5.
Commercial
15.7.3.2.
India
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By Drug
15.7.3.2.1.
Blinatumomab
15.7.3.2.2.
Emicizumab
15.7.3.2.3.
Amivantamab-vmjw
15.7.3.2.4.
Mosunetuzumab
15.7.3.2.5.
Others
15.7.3.3.
India
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
15.7.3.3.1.
Intravenous
15.7.3.3.2.
Subcutaneous
15.7.3.4.
India
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Application
15.7.3.4.1.
Cancer
15.7.3.4.2.
Autoimmune
Diseases
15.7.3.4.3.
Infectious
Diseases
15.7.3.4.4.
Neurologic
Diseases
15.7.3.4.5.
Cardiovascular
Diseases
15.7.3.4.6.
Others
15.7.3.5.
India
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
End-User
15.7.3.5.1.
Hospitals
15.7.3.5.2.
Specialty
clinics
15.7.3.5.3.
Research
Institutions
15.7.3.5.4.
Others
15.7.4. New Zealand
15.7.4.1.
New
Zealand Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts,
By Clinical Trials
15.7.4.1.1.
Preclinical
15.7.4.1.2.
Phase I
15.7.4.1.3.
Phase II
15.7.4.1.4.
Phase
III
15.7.4.1.5.
Commercial
15.7.4.2.
New
Zealand Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts,
By Drug
15.7.4.2.1.
Blinatumomab
15.7.4.2.2.
Emicizumab
15.7.4.2.3.
Amivantamab-vmjw
15.7.4.2.4.
Mosunetuzumab
15.7.4.2.5.
Others
15.7.4.3.
New
Zealand Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts,
By Route of Administration
15.7.4.3.1.
Intravenous
15.7.4.3.2.
Subcutaneous
15.7.4.4.
New
Zealand Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts,
By Application
15.7.4.4.1.
Cancer
15.7.4.4.2.
Autoimmune
Diseases
15.7.4.4.3.
Infectious
Diseases
15.7.4.4.4.
Neurologic
Diseases
15.7.4.4.5.
Cardiovascular
Diseases
15.7.4.4.6.
Others
15.7.4.5.
New
Zealand Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts,
By End-User
15.7.4.5.1.
Hospitals
15.7.4.5.2.
Specialty
clinics
15.7.4.5.3.
Research
Institutions
15.7.4.5.4.
Others
15.7.5. Australia
15.7.5.1.
Australia
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Clinical Trials
15.7.5.1.1.
Preclinical
15.7.5.1.2.
Phase I
15.7.5.1.3.
Phase II
15.7.5.1.4.
Phase
III
15.7.5.1.5.
Commercial
15.7.5.2.
Australia
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By Drug
15.7.5.2.1.
Blinatumomab
15.7.5.2.2.
Emicizumab
15.7.5.2.3.
Amivantamab-vmjw
15.7.5.2.4.
Mosunetuzumab
15.7.5.2.5.
Others
15.7.5.3.
Australia
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
15.7.5.3.1.
Intravenous
15.7.5.3.2.
Subcutaneous
15.7.5.4.
Australia
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Application
15.7.5.4.1.
Cancer
15.7.5.4.2.
Autoimmune
Diseases
15.7.5.4.3.
Infectious
Diseases
15.7.5.4.4.
Neurologic
Diseases
15.7.5.4.5.
Cardiovascular
Diseases
15.7.5.4.6.
Others
15.7.5.5.
Australia
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
End-User
15.7.5.5.1.
Hospitals
15.7.5.5.2.
Specialty
clinics
15.7.5.5.3.
Research
Institutions
15.7.5.5.4.
Others
15.7.6. South Korea
15.7.6.1.
South
Korea Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Clinical Trials
15.7.6.1.1.
Preclinical
15.7.6.1.2.
Phase I
15.7.6.1.3.
Phase II
15.7.6.1.4.
Phase
III
15.7.6.1.5.
Commercial
15.7.6.2.
South
Korea Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Drug
15.7.6.2.1.
Blinatumomab
15.7.6.2.2.
Emicizumab
15.7.6.2.3.
Amivantamab-vmjw
15.7.6.2.4.
Mosunetuzumab
15.7.6.2.5.
Others
15.7.6.3.
South
Korea Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
15.7.6.3.1.
Intravenous
15.7.6.3.2.
Subcutaneous
15.7.6.4.
South
Korea Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By Application
15.7.6.4.1.
Cancer
15.7.6.4.2.
Autoimmune
Diseases
15.7.6.4.3.
Infectious
Diseases
15.7.6.4.4.
Neurologic
Diseases
15.7.6.4.5.
Cardiovascular
Diseases
15.7.6.4.6.
Others
15.7.6.5.
South
Korea Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
End-User
15.7.6.5.1.
Hospitals
15.7.6.5.2.
Specialty
clinics
15.7.6.5.3.
Research
Institutions
15.7.6.5.4.
Others
15.7.7. Southeast Asia
15.7.7.1.
Southeast
Asia Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Clinical Trials
15.7.7.1.1.
Preclinical
15.7.7.1.2.
Phase I
15.7.7.1.3.
Phase II
15.7.7.1.4.
Phase
III
15.7.7.1.5.
Commercial
15.7.7.2.
Southeast
Asia Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Drug
15.7.7.2.1.
Blinatumomab
15.7.7.2.2.
Emicizumab
15.7.7.2.3.
Amivantamab-vmjw
15.7.7.2.4.
Mosunetuzumab
15.7.7.2.5.
Others
15.7.7.3.
Southeast
Asia Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
15.7.7.3.1.
Intravenous
15.7.7.3.2.
Subcutaneous
15.7.7.4.
Southeast
Asia Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Application
15.7.7.4.1.
Cancer
15.7.7.4.2.
Autoimmune
Diseases
15.7.7.4.3.
Infectious
Diseases
15.7.7.4.4.
Neurologic
Diseases
15.7.7.4.5.
Cardiovascular
Diseases
15.7.7.4.6.
Others
15.7.7.5.
Southeast
Asia Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
End-User
15.7.7.5.1.
Hospitals
15.7.7.5.2.
Specialty
clinics
15.7.7.5.3.
Research
Institutions
15.7.7.5.4.
Others
15.7.7.6.
Southeast
Asia Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Country
15.7.7.6.1.
Indonesia
15.7.7.6.2.
Thailand
15.7.7.6.3.
Malaysia
15.7.7.6.4.
Singapore
15.7.7.6.5.
Rest of
Southeast Asia
15.7.8. Rest of Asia Pacific
15.7.8.1.
Rest of
Asia Pacific Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and
Forecasts, By Clinical Trials
15.7.8.1.1.
Preclinical
15.7.8.1.2.
Phase I
15.7.8.1.3.
Phase II
15.7.8.1.4.
Phase
III
15.7.8.1.5.
Commercial
15.7.8.2.
Rest of
Asia Pacific Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and
Forecasts, By Drug
15.7.8.2.1.
Blinatumomab
15.7.8.2.2.
Emicizumab
15.7.8.2.3.
Amivantamab-vmjw
15.7.8.2.4.
Mosunetuzumab
15.7.8.2.5.
Others
15.7.8.3.
Rest of
Asia Pacific Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
15.7.8.3.1.
Intravenous
15.7.8.3.2.
Subcutaneous
15.7.8.4.
Rest of
Asia Pacific Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and
Forecasts, By Application
15.7.8.4.1.
Cancer
15.7.8.4.2.
Autoimmune
Diseases
15.7.8.4.3.
Infectious
Diseases
15.7.8.4.4.
Neurologic
Diseases
15.7.8.4.5.
Cardiovascular
Diseases
15.7.8.4.6.
Others
15.7.8.5.
Rest of
Asia Pacific Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and
Forecasts, By End-User
15.7.8.5.1.
Hospitals
15.7.8.5.2.
Specialty
clinics
15.7.8.5.3.
Research
Institutions
15.7.8.5.4.
Others
15.8. Key Segment for Channeling Investments
15.8.1. By Country
15.8.2. By Clinical Trials
15.8.3. By Drug
15.8.4. By Route of Administration
15.8.5. By Application
15.8.6. By End-User
16. Middle East and Africa Bi-Specific
Antibodies Therapy Market Analysis and Forecasts, 2022 – 2030
16.1. Overview
16.1.1. Middle East and Africa Bi-Specific Antibodies
Therapy Market Revenue (US$ Mn)
16.2. Middle East and Africa Bi-Specific Antibodies
Therapy Market Revenue (US$ Mn) and Forecasts, By Clinical Trials
16.2.1. Preclinical
16.2.2. Phase I
16.2.3. Phase II
16.2.4. Phase III
16.2.5. Commercial
16.3. Middle East and Africa Bi-Specific Antibodies
Therapy Market Revenue (US$ Mn) and Forecasts, By Drug
16.3.1. Blinatumomab
16.3.2. Emicizumab
16.3.3. Amivantamab-vmjw
16.3.4. Mosunetuzumab
16.3.5. Others
16.4. Middle East and Africa Bi-Specific Antibodies
Therapy Market Revenue (US$ Mn) and Forecasts, By Route of Administration
16.4.1. Intravenous
16.4.2. Subcutaneous
16.5. Middle East and Africa Bi-Specific Antibodies
Therapy Market Revenue (US$ Mn) and Forecasts, By Application
16.5.1. Cancer
16.5.2. Autoimmune Diseases
16.5.3. Infectious Diseases
16.5.4. Neurologic Diseases
16.5.5. Cardiovascular Diseases
16.5.6. Others
16.6. Middle East and Africa Bi-Specific Antibodies
Therapy Market Revenue (US$ Mn) and Forecasts, By End-User
16.6.1. Hospitals
16.6.2. Specialty clinics
16.6.3. Research Institutions
16.6.4. Others
16.7. Middle East and Africa Bi-Specific Antibodies
Therapy Market Revenue (US$ Mn) and Forecasts, By Country
16.7.1. Saudi Arabia
16.7.1.1.
Saudi
Arabia Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Clinical Trials
16.7.1.1.1.
Preclinical
16.7.1.1.2.
Phase I
16.7.1.1.3.
Phase II
16.7.1.1.4.
Phase III
16.7.1.1.5.
Commercial
16.7.1.2.
Saudi
Arabia Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Drug
16.7.1.2.1.
Blinatumomab
16.7.1.2.2.
Emicizumab
16.7.1.2.3.
Amivantamab-vmjw
16.7.1.2.4.
Mosunetuzumab
16.7.1.2.5.
Others
16.7.1.3.
Saudi
Arabia Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
16.7.1.3.1.
Intravenous
16.7.1.3.2.
Subcutaneous
16.7.1.4.
Saudi
Arabia Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Application
16.7.1.4.1.
Cancer
16.7.1.4.2.
Autoimmune
Diseases
16.7.1.4.3.
Infectious
Diseases
16.7.1.4.4.
Neurologic
Diseases
16.7.1.4.5.
Cardiovascular
Diseases
16.7.1.4.6.
Others
16.7.1.5.
Saudi
Arabia Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
End-User
16.7.1.5.1.
Hospitals
16.7.1.5.2.
Specialty
clinics
16.7.1.5.3.
Research
Institutions
16.7.1.5.4.
Others
16.7.2. UAE
16.7.2.1.
UAE
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Clinical Trials
16.7.2.1.1.
Preclinical
16.7.2.1.2.
Phase I
16.7.2.1.3.
Phase II
16.7.2.1.4.
Phase
III
16.7.2.1.5.
Commercial
16.7.2.2.
UAE
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By Drug
16.7.2.2.1.
Blinatumomab
16.7.2.2.2.
Emicizumab
16.7.2.2.3.
Amivantamab-vmjw
16.7.2.2.4.
Mosunetuzumab
16.7.2.2.5.
Others
16.7.2.3.
UAE
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
16.7.2.3.1.
Intravenous
16.7.2.3.2.
Subcutaneous
16.7.2.4.
UAE
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Application
16.7.2.4.1.
Cancer
16.7.2.4.2.
Autoimmune
Diseases
16.7.2.4.3.
Infectious
Diseases
16.7.2.4.4.
Neurologic
Diseases
16.7.2.4.5.
Cardiovascular
Diseases
16.7.2.4.6.
Others
16.7.2.5.
UAE
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
End-User
16.7.2.5.1.
Hospitals
16.7.2.5.2.
Specialty
clinics
16.7.2.5.3.
Research
Institutions
16.7.2.5.4.
Others
16.7.3. Egypt
16.7.3.1.
Egypt
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Clinical Trials
16.7.3.1.1.
Preclinical
16.7.3.1.2.
Phase I
16.7.3.1.3.
Phase II
16.7.3.1.4.
Phase III
16.7.3.1.5.
Commercial
16.7.3.2.
Egypt
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By Drug
16.7.3.2.1.
Blinatumomab
16.7.3.2.2.
Emicizumab
16.7.3.2.3.
Amivantamab-vmjw
16.7.3.2.4.
Mosunetuzumab
16.7.3.2.5.
Others
16.7.3.3.
Egypt
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
16.7.3.3.1.
Intravenous
16.7.3.3.2.
Subcutaneous
16.7.3.4.
Egypt
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Application
16.7.3.4.1.
Cancer
16.7.3.4.2.
Autoimmune
Diseases
16.7.3.4.3.
Infectious
Diseases
16.7.3.4.4.
Neurologic
Diseases
16.7.3.4.5.
Cardiovascular
Diseases
16.7.3.4.6.
Others
16.7.3.5.
Egypt
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
End-User
16.7.3.5.1.
Hospitals
16.7.3.5.2.
Specialty
clinics
16.7.3.5.3.
Research
Institutions
16.7.3.5.4.
Others
16.7.4. Kuwait
16.7.4.1.
Kuwait
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Clinical Trials
16.7.4.1.1.
Preclinical
16.7.4.1.2.
Phase I
16.7.4.1.3.
Phase II
16.7.4.1.4.
Phase III
16.7.4.1.5.
Commercial
16.7.4.2.
Kuwait
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By Drug
16.7.4.2.1.
Blinatumomab
16.7.4.2.2.
Emicizumab
16.7.4.2.3.
Amivantamab-vmjw
16.7.4.2.4.
Mosunetuzumab
16.7.4.2.5.
Others
16.7.4.3.
Kuwait
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
16.7.4.3.1.
Intravenous
16.7.4.3.2.
Subcutaneous
16.7.4.4.
Kuwait
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Application
16.7.4.4.1.
Cancer
16.7.4.4.2.
Autoimmune
Diseases
16.7.4.4.3.
Infectious
Diseases
16.7.4.4.4.
Neurologic
Diseases
16.7.4.4.5.
Cardiovascular
Diseases
16.7.4.4.6.
Others
16.7.4.5.
Kuwait
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
End-User
16.7.4.5.1.
Hospitals
16.7.4.5.2.
Specialty
clinics
16.7.4.5.3.
Research
Institutions
16.7.4.5.4.
Others
16.7.5. South Africa
16.7.5.1.
South
Africa Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Clinical Trials
16.7.5.1.1.
Preclinical
16.7.5.1.2.
Phase I
16.7.5.1.3.
Phase II
16.7.5.1.4.
Phase
III
16.7.5.1.5.
Commercial
16.7.5.2.
South
Africa Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Drug
16.7.5.2.1.
Blinatumomab
16.7.5.2.2.
Emicizumab
16.7.5.2.3.
Amivantamab-vmjw
16.7.5.2.4.
Mosunetuzumab
16.7.5.2.5.
Others
16.7.5.3.
South
Africa Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
16.7.5.3.1.
Intravenous
16.7.5.3.2.
Subcutaneous
16.7.5.4.
South
Africa Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Application
16.7.5.4.1.
Cancer
16.7.5.4.2.
Autoimmune
Diseases
16.7.5.4.3.
Infectious
Diseases
16.7.5.4.4.
Neurologic
Diseases
16.7.5.4.5.
Cardiovascular
Diseases
16.7.5.4.6.
Others
16.7.5.5.
South
Africa Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
End-User
16.7.5.5.1.
Hospitals
16.7.5.5.2.
Specialty
clinics
16.7.5.5.3.
Research
Institutions
16.7.5.5.4.
Others
16.7.6. Rest of Middle East & Africa
16.7.6.1.
Rest of
Middle East & Africa Bi-Specific Antibodies Therapy Market Revenue (US$ Mn)
and Forecasts, By Clinical Trials
16.7.6.1.1.
Preclinical
16.7.6.1.2.
Phase I
16.7.6.1.3.
Phase II
16.7.6.1.4.
Phase
III
16.7.6.1.5.
Commercial
16.7.6.2.
Rest of
Middle East & Africa Bi-Specific Antibodies Therapy Market Revenue (US$ Mn)
and Forecasts, By Drug
16.7.6.2.1.
Blinatumomab
16.7.6.2.2.
Emicizumab
16.7.6.2.3.
Amivantamab-vmjw
16.7.6.2.4.
Mosunetuzumab
16.7.6.2.5.
Others
16.7.6.3.
Rest of
Middle East & Africa Bi-Specific Antibodies Therapy Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
16.7.6.3.1.
Intravenous
16.7.6.3.2.
Subcutaneous
16.7.6.4.
Rest of
Middle East & Africa Bi-Specific Antibodies Therapy Market Revenue (US$ Mn)
and Forecasts, By Application
16.7.6.4.1.
Cancer
16.7.6.4.2.
Autoimmune
Diseases
16.7.6.4.3.
Infectious
Diseases
16.7.6.4.4.
Neurologic
Diseases
16.7.6.4.5.
Cardiovascular
Diseases
16.7.6.4.6.
Others
16.7.6.5.
Rest of
Middle East & Africa Bi-Specific Antibodies Therapy Market Revenue (US$ Mn)
and Forecasts, By End-User
16.7.6.5.1.
Hospitals
16.7.6.5.2.
Specialty
clinics
16.7.6.5.3.
Research
Institutions
16.7.6.5.4.
Others
16.8. Key Segment for Channeling Investments
16.8.1. By Country
16.8.2. By Clinical Trials
16.8.3. By Drug
16.8.4. By Route of Administration
16.8.5. By Application
16.8.6. By End-User
17. Latin America Bi-Specific Antibodies Therapy
Market Analysis and Forecasts, 2022 – 2030
17.1. Overview
17.1.1. Latin America Bi-Specific Antibodies Therapy
Market Revenue (US$ Mn)
17.2. Latin America Bi-Specific Antibodies Therapy
Market Revenue (US$ Mn) and Forecasts, By Clinical Trials
17.2.1. Preclinical
17.2.2. Phase I
17.2.3. Phase II
17.2.4. Phase III
17.2.5. Commercial
17.3. Latin America Bi-Specific Antibodies Therapy
Market Revenue (US$ Mn) and Forecasts, By Drug
17.3.1. Blinatumomab
17.3.2. Emicizumab
17.3.3. Amivantamab-vmjw
17.3.4. Mosunetuzumab
17.3.5. Others
17.4. Latin America Bi-Specific Antibodies Therapy
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
17.4.1. Intravenous
17.4.2. Subcutaneous
17.5. Latin America Bi-Specific Antibodies Therapy
Market Revenue (US$ Mn) and Forecasts, By Application
17.5.1. Cancer
17.5.2. Autoimmune Diseases
17.5.3. Infectious Diseases
17.5.4. Neurologic Diseases
17.5.5. Cardiovascular Diseases
17.5.6. Others
17.6. Latin America Bi-Specific Antibodies Therapy
Market Revenue (US$ Mn) and Forecasts, By End-User
17.6.1. Hospitals
17.6.2. Specialty clinics
17.6.3. Research Institutions
17.6.4. Others
17.7. Latin America Bi-Specific Antibodies Therapy
Market Revenue (US$ Mn) and Forecasts, By Country
17.7.1. Brazil
17.7.1.1.
Brazil
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Clinical Trials
17.7.1.1.1.
Preclinical
17.7.1.1.2.
Phase I
17.7.1.1.3.
Phase II
17.7.1.1.4.
Phase
III
17.7.1.1.5.
Commercial
17.7.1.2.
Brazil
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By Drug
17.7.1.2.1.
Blinatumomab
17.7.1.2.2.
Emicizumab
17.7.1.2.3.
Amivantamab-vmjw
17.7.1.2.4.
Mosunetuzumab
17.7.1.2.5.
Others
17.7.1.3.
Brazil Bi-Specific
Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
17.7.1.3.1.
Intravenous
17.7.1.3.2.
Subcutaneous
17.7.1.4.
Brazil
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Application
17.7.1.4.1.
Cancer
17.7.1.4.2.
Autoimmune
Diseases
17.7.1.4.3.
Infectious
Diseases
17.7.1.4.4.
Neurologic
Diseases
17.7.1.4.5.
Cardiovascular
Diseases
17.7.1.4.6.
Others
17.7.1.5.
Brazil
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
End-User
17.7.1.5.1.
Hospitals
17.7.1.5.2.
Specialty
clinics
17.7.1.5.3.
Research
Institutions
17.7.1.5.4.
Others
17.7.2. Argentina
17.7.2.1.
Argentina
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Clinical Trials
17.7.2.1.1.
Preclinical
17.7.2.1.2.
Phase I
17.7.2.1.3.
Phase II
17.7.2.1.4.
Phase
III
17.7.2.1.5.
Commercial
17.7.2.2.
Argentina
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By Drug
17.7.2.2.1.
Blinatumomab
17.7.2.2.2.
Emicizumab
17.7.2.2.3.
Amivantamab-vmjw
17.7.2.2.4.
Mosunetuzumab
17.7.2.2.5.
Others
17.7.2.3.
Argentina
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
17.7.2.3.1.
Intravenous
17.7.2.3.2.
Subcutaneous
17.7.2.4.
Argentina
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
Application
17.7.2.4.1.
Cancer
17.7.2.4.2.
Autoimmune
Diseases
17.7.2.4.3.
Infectious
Diseases
17.7.2.4.4.
Neurologic
Diseases
17.7.2.4.5.
Cardiovascular
Diseases
17.7.2.4.6.
Others
17.7.2.5.
Argentina
Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts, By
End-User
17.7.2.5.1.
Hospitals
17.7.2.5.2.
Specialty
clinics
17.7.2.5.3.
Research
Institutions
17.7.2.5.4.
Others
17.7.3. Rest of Latin America
17.7.3.1.
Rest of Latin
America Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and Forecasts,
By Clinical Trials
17.7.3.1.1.
Preclinical
17.7.3.1.2.
Phase I
17.7.3.1.3.
Phase II
17.7.3.1.4.
Phase
III
17.7.3.1.5.
Commercial
17.7.3.2.
Rest of
Latin America Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and
Forecasts, By Drug
17.7.3.2.1.
Blinatumomab
17.7.3.2.2.
Emicizumab
17.7.3.2.3.
Amivantamab-vmjw
17.7.3.2.4.
Mosunetuzumab
17.7.3.2.5.
Others
17.7.3.3.
Rest of
Latin America Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
17.7.3.3.1.
Intravenous
17.7.3.3.2.
Subcutaneous
17.7.3.4.
Rest of
Latin America Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and
Forecasts, By Application
17.7.3.4.1.
Cancer
17.7.3.4.2.
Autoimmune
Diseases
17.7.3.4.3.
Infectious
Diseases
17.7.3.4.4.
Neurologic
Diseases
17.7.3.4.5.
Cardiovascular
Diseases
17.7.3.4.6.
Others
17.7.3.5.
Rest of
Latin America Bi-Specific Antibodies Therapy Market Revenue (US$ Mn) and
Forecasts, By End-User
17.7.3.5.1.
Hospitals
17.7.3.5.2.
Specialty
clinics
17.7.3.5.3.
Research
Institutions
17.7.3.5.4.
Others
17.8. Key Segment for Channeling Investments
17.8.1. By Country
17.8.2. By Clinical Trials
17.8.3. By Drug
17.8.4. By Route of Administration
17.8.5. By Application
17.8.6. By End-User
18. Competitive Benchmarking
18.1. Brand Benchmarking
18.2. Market Share Analysis, 2021
18.3. Global Presence and Growth Strategies
18.3.1. Mergers and Acquisitions
18.3.2. Product Launches
18.3.3. Investments Trends
18.3.4. R&D Initiatives
19. Player Profiles
19.1. Affimed GmbH
19.1.1. Company Details
19.1.2. Company Overview
19.1.3. Product Offerings
19.1.4. Key Developments
19.1.5. Financial Analysis
19.1.6. SWOT Analysis
19.1.7. Business Strategies
19.2. Amgen Inc.
19.2.1. Company Details
19.2.2. Company Overview
19.2.3. Product Offerings
19.2.4. Key Developments
19.2.5. Financial Analysis
19.2.6. SWOT Analysis
19.2.7. Business Strategies
19.3. AstraZeneca
19.3.1. Company Details
19.3.2. Company Overview
19.3.3. Product Offerings
19.3.4. Key Developments
19.3.5. Financial Analysis
19.3.6. SWOT Analysis
19.3.7. Business Strategies
19.4. Biomunex
19.4.1. Company Details
19.4.2. Company Overview
19.4.3. Product Offerings
19.4.4. Key Developments
19.4.5. Financial Analysis
19.4.6. SWOT Analysis
19.4.7. Business Strategies
19.5. Creative- Biolabs
19.5.1. Company Details
19.5.2. Company Overview
19.5.3. Product Offerings
19.5.4. Key Developments
19.5.5. Financial Analysis
19.5.6. SWOT Analysis
19.5.7. Business Strategies
19.6. Emergent BioSolutions Inc.
19.6.1. Company Details
19.6.2. Company Overview
19.6.3. Product Offerings
19.6.4. Key Developments
19.6.5. Financial Analysis
19.6.6. SWOT Analysis
19.6.7. Business Strategies
19.7. F. Hoffmann-La Roche Ltd
19.7.1. Company Details
19.7.2. Company Overview
19.7.3. Product Offerings
19.7.4. Key Developments
19.7.5. Financial Analysis
19.7.6. SWOT Analysis
19.7.7. Business Strategies
19.8. F-star Therapeutics Inc.
19.8.1. Company Details
19.8.2. Company Overview
19.8.3. Product Offerings
19.8.4. Key Developments
19.8.5. Financial Analysis
19.8.6. SWOT Analysis
19.8.7. Business Strategies
19.9. Genentech USA, Inc.
19.9.1. Company Details
19.9.2. Company Overview
19.9.3. Product Offerings
19.9.4. Key Developments
19.9.5. Financial Analysis
19.9.6. SWOT Analysis
19.9.7. Business Strategies
19.10. Genmab A/S
19.10.1. Company Details
19.10.2. Company Overview
19.10.3. Product Offerings
19.10.4. Key Developments
19.10.5. Financial Analysis
19.10.6. SWOT Analysis
19.10.7. Business Strategies
19.11. Johnson & Johnson
19.11.1. Company Details
19.11.2. Company Overview
19.11.3. Product Offerings
19.11.4. Key Developments
19.11.5. Financial Analysis
19.11.6. SWOT Analysis
19.11.7. Business Strategies
19.12. MacroGenics, Inc.
19.12.1. Company Details
19.12.2. Company Overview
19.12.3. Product Offerings
19.12.4. Key Developments
19.12.5. Financial Analysis
19.12.6. SWOT Analysis
19.12.7. Business Strategies
19.13. Merck KGaA
19.13.1. Company Details
19.13.2. Company Overview
19.13.3. Product Offerings
19.13.4. Key Developments
19.13.5. Financial Analysis
19.13.6. SWOT Analysis
19.13.7. Business Strategies
19.14. Merus
19.14.1. Company Details
19.14.2. Company Overview
19.14.3. Product Offerings
19.14.4. Key Developments
19.14.5. Financial Analysis
19.14.6. SWOT Analysis
19.14.7. Business Strategies
19.15. Pfizer Inc.
19.15.1. Company Details
19.15.2. Company Overview
19.15.3. Product Offerings
19.15.4. Key Developments
19.15.5. Financial Analysis
19.15.6. SWOT Analysis
19.15.7. Business Strategies
19.16. Pieris
19.16.1. Company Details
19.16.2. Company Overview
19.16.3. Product Offerings
19.16.4. Key Developments
19.16.5. Financial Analysis
19.16.6. SWOT Analysis
19.16.7. Business Strategies
19.17. Other Market Participants
20. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User
and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.